Labetalol Hydrochloride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318083

CAS#: 32780-64-6 (HCl)

Description: Labetalol is a mixed alpha/beta adrenergic antagonist that is used to treat high blood pressure. It can be given intravenously in severe hypertensive situations, or by mouth for long term hypertension management. Studies suggest that the pharmacokinetics of labetalol are significantly affected by the common CYP2C19 polymorphisms.


Chemical Structure

img
Labetalol Hydrochloride
CAS# 32780-64-6 (HCl)

Theoretical Analysis

MedKoo Cat#: 318083
Name: Labetalol Hydrochloride
CAS#: 32780-64-6 (HCl)
Chemical Formula: C19H25ClN2O3
Exact Mass:
Molecular Weight: 364.87
Elemental Analysis: C, 62.55; H, 6.91; Cl, 9.72; N, 7.68; O, 13.15

Price and Availability

Size Price Availability Quantity
1.0g USD 150.0 2 Weeks
2.0g USD 250.0 2 Weeks
5.0g USD 450.0 2 Weeks
10.0g USD 650.0 2 Weeks
20.0g USD 950.0 2 Weeks
50.0g USD 1650.0 2 Weeks
Bulk inquiry

Related CAS #: 32780-64-6 (HCl)   36894-69-6 (free)    

Synonym: Labetalol, Normodyne, Trandate, Albetol, Apo-Labetalol, Dilevalol

IUPAC/Chemical Name: 2-hydroxy-5-[1-hydroxy-2-(4-phenylbutan-2-ylamino)ethyl]benzamide hydrochloride

InChi Key: WQVZLXWQESQGIF-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H24N2O3.ClH/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24;/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24);1H

SMILES Code: O=C(N)C1=CC(C(O)CNC(CCC2=CC=CC=C2)C)=CC=C1O.[H]Cl

Appearance: White to off-white crystalline powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 364.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Shekhar S, Gupta N, Kirubakaran R, Pareek P. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG. 2016 Jan;123(1):40-7. doi: 10.1111/1471-0528.13463. Epub 2015 Jun 26. Review. PubMed PMID: 26113232.

2: Magee LA, Namouz-Haddad S, Cao V, Koren G, von Dadelszen P. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015 Mar;14(3):453-61. doi: 10.1517/14740338.2015.998197. Review. PubMed PMID: 25692529.

3: Peacock WF 4th, Hilleman DE, Levy PD, Rhoney DH, Varon J. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012 Jul;30(6):981-93. doi: 10.1016/j.ajem.2011.06.040. Epub 2011 Sep 9. Review. PubMed PMID: 21908132.

4: Stumpf JL. Fatal hepatotoxicity induced by hydralazine or labetalol. Pharmacotherapy. 1991;11(5):415-8. Review. PubMed PMID: 1745625.

5: Walker HJ, Geniton DJ. Vasodilator therapy and the anesthetist: a review of nitroprusside, labetalol, hydralazine and nitroglycerin. AANA J. 1989 Oct;57(5):435-44. Review. PubMed PMID: 2690553.

6: Goa KL, Benfield P, Sorkin EM. Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease. Drugs. 1989 May;37(5):583-627. Review. PubMed PMID: 2663413.

7: Fox K, Quyyumi AA. Labetalol in normotensive patients with angina pectoris. Cardiovasc Drugs Ther. 1988 Sep;2(3):363-7. Review. PubMed PMID: 3154918.

8: Frishman WH. Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia. Cardiovasc Drugs Ther. 1988 Sep;2(3):343-53. Review. PubMed PMID: 2908732.

9: Lund-Johansen P. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. Drugs. 1984;28 Suppl 2:35-50. Review. PubMed PMID: 6151890.

10: Wallin JD, O'Neill WM Jr. Labetalol. Current research and therapeutic status. Arch Intern Med. 1983 Mar;143(3):485-90. Review. PubMed PMID: 6338850.

11: Prichard BN, Richards DA. Comparison of labetalol with other anti-hypertensive drugs. Br J Clin Pharmacol. 1982 Jun;13(1 Suppl):41S-47S. Review. PubMed PMID: 6124265; PubMed Central PMCID: PMC1401845.

12: Reid JL, Meredith PA, Elliott HL. Labetalol and the management of hypertension. J Cardiovasc Pharmacol. 1981;3 Suppl 1:S60-8. Review. PubMed PMID: 6169961.

13: Prichard BN, Richards DA. The pharmacological basis for the use of labetalol in the treatment of hypertension. J Cardiovasc Pharmacol. 1981;3 Suppl 1:S24-9. Review. PubMed PMID: 6169957.

14: Richards DA, Prichard BN. Clinical pharmacology of labetalol. Br J Clin Pharmacol. 1979;8(Suppl 2):89S-93S. Review. PubMed PMID: 43165; PubMed Central PMCID: PMC1429754.

15: Brogden RN, Heel RC, Speight TM, Avery GS. Labetalol: a review of its pharmacology and therapeutic use in hypertension. Drugs. 1978 Apr;15(4):251-70. Review. PubMed PMID: 25757.

16: Blakeley AG, Summers RJ. The pharmacology of labetalol, an alpha- and beta-adrenoceptor blocking agent. Gen Pharmacol. 1978;9(6):399-402. Review. PubMed PMID: 32121.

17: Brittain RT, Levy GP. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):681-4. Review. PubMed PMID: 10948.

18: Harrington C. Managing hypertension in patients with stroke. Are you prepared for labetalol infusion? Crit Care Nurse. 2003 Jun;23(3):30-8. Review. PubMed PMID: 12830778.

19: Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha- and beta-adrenergic receptors. Cleve Clin J Med. 1994 Jan-Feb;61(1):59-69; quiz 80-2. Review. PubMed PMID: 8124849.

20: Donnelly R, Macphee GJ. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. Clin Pharmacokinet. 1991 Aug;21(2):95-109. Review. PubMed PMID: 1884570.

1: Chan SW, Hu M, Ko SS, Tam CW, Fok BS, Yin OQ, Chow MS, Tomlinson B. CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. Eur J Clin Pharmacol. 2013 Apr;69(4):799-806. doi: 10.1007/s00228-012-1428-x. Epub 2012 Oct 23. PubMed PMID: 23090703.



Additional Information

Related CAS#
32780-64-6 (Labetalol hydrochloride)
36894-69-6 (Labetalol free base)